. 2018 Jun 13;25(Suppl 1):S94–S102. doi: 10.3747/co.25.3750

TABLE III.

Combination immunotherapy plus chemotherapy in the first-line setting

Trial	Agents		Pts (n)	ORR (%)

	Immunotherapy	Chemotherapy
GP28328³²	Atezolizumab	Carboplatin–paclitaxel	8	50
		Carboplatin–pemetrexed	17	77
		Carboplatin–nab-paclitaxel	16	56
KEYNOTE 021³³	Pembrolizumab	Carboplatin–paclitaxel with bevacizumab	25	52
		Carboplatin–paclitaxel	25	48
		Carboplatin–pemetrexed	24	71
CheckMate 012³⁴	Nivolumab
	(10 mg)	Cisplatin–gemcitabine	12	33
	(10 mg)	Cisplatin–pemetrexed	15	47
	(10 mg)	Carboplatin–paclitaxel	15	47
	(5 mg)	Carboplatin–paclitaxel	14	43

ORR = objective response rate.